Form 8-K · Current Report · Filed 2024-02-15
DexCom, Inc. Terminates Outstanding Warrants with Bank of America
On February 13, 2024, DexCom, Inc. entered into an agreement with Bank of America, N.A. to terminate outstanding warrants to purchase up to 10.3 million shares of the Company's common stock. The termination is in connection with the expiration of the Company's 0.75% Convertible Senior Notes due 2023 and convertible note hedge transactions with Bank of America and JPMorgan Chase Bank, National Association. DexCom will deliver shares of Common Stock to Bank of America based on the daily volume-weighted average price during an averaging period expected to be completed in the first quarter of 2024.
- Filer
- Dexcom Inc. DXCM · NASDAQ
- Filed
- Accession
- 0001093557-24-000024
- CIK
- 0001093557
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Entry into a Material Definitive Agreement
Termination of a Material Definitive Agreement
Unregistered Sales of Equity Securities
Financial Statements and Exhibits
Market reaction
Close before filing
$116.75
Next session
+0.3%
Since filing
-28.5%
Latest close
$83.45
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from DXCM reporting the same item, with the next session's move:
Exhibits (1)
About Dexcom Inc.
Dexcom Inc. is a prominent player in the medical technology sector, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The company's primary function is to develop and distribute innovative CGM devices that provide real-time glucose readings, allowing individuals with diabetes to make informed decisions about their health. Dexcom’s products play a critical role in healthcare by offering an alternative to traditional fingerstick testing, thus improving quality of life for many users. The company impacts several sectors, most notably within healthcare and technology, by integrating advanced data analytics and wireless technology into its monitoring systems. This not only aids individuals in managing their glucose levels but also supports healthcare providers in delivering better patient care through data-driven insights. In the financial market, Dexcom Inc. is recognized for its contributions to the growing field of digital health solutions. The company has established itself as a leader in its niche, continuously pushing the boundaries of technology to offer more precise and user-friendly glucose monitoring options. Founded in 1999 and headquartered in San Diego, California, Dexcom remains at the forefront of diabetes management solutions.
Never miss another DXCM filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.